CAS NO: | 442-51-3 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
500mg | 电议 |
1 g | 电议 |
5 g | 电议 |
10 g | 电议 |
生物活性 | Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of5-HT2Aserotonin receptor, with anKiof 397 nM[1]. | ||||||||||||||||
IC50& Target[1][2] |
| ||||||||||||||||
体外研究 (In Vitro) | Harmine inhibits tau phosphorylation by DYRK1A by selected DANDYs, with an IC50of 190 nM[2].Harmine negatively regulates homologous recombination (HR) by interfering Rad51 recruitment, resulting in severe cytotoxicity in hepatoma cells. Furthermore, NHEJ inhibitor Nu7441 markedly sensitizes Hep3B cells to the anti-proliferative effects of Harmine[3]. | ||||||||||||||||
体内研究 (In Vivo) | It is shown that brain water content is significantly increased in the TBI group. Treatment with Harmine significantly reduces the tissue water content at 1, 3 and 5 days, compared with the TBI group. Harmine treatment significantly reduces the escape latency at 3 and 5 days, compared with the TBI group. Post-TBI administration of Harmine significantly improves the motor function recovery of the rats at 1, 3 and 5 days following TBI, compared with the TBI group without Harmine treatment. The neuronal survival rate in the Harmine-treated group is significantly increased, compared with the TBI group. Administration of Harmine results in marked elevation in the expression of GLT-1, compared with the TBI group. The administration of Harmine significantly reduces the expression of caspase 3, compared with the TBI group[4]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 212.25 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C13H12N2O | ||||||||||||||||
CAS 号 | 442-51-3 | ||||||||||||||||
中文名称 | 去氢骆驼蓬碱;肉叶芸香碱;哈尔明碱 | ||||||||||||||||
结构分类 |
| ||||||||||||||||
来源 |
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 30 mg/mL(141.34 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|